Comparing Two Different Doses of Intravenous Midazolam in Pediatric Sedation and Analgesia

Area of Science:

• Pediatric Anesthesiology
• Clinical Pharmacology

Background:

• Midazolam is widely used for pediatric procedural sedation and analgesia.
• Limited data exists on optimal dosing and side effects in Iranian children.
• This study addresses the need for evidence-based midazolam protocols in this population.

Purpose of the Study:

• To compare the efficacy and safety of two intravenous (IV) midazolam doses (0.1 mg/kg vs. 0.3 mg/kg) for procedural sedation in Iranian infants.
• To evaluate the onset and duration of action, success rates, and adverse events associated with each midazolam dose.

Main Methods:

• A randomized clinical trial involving 110 infants under 2 years old with stable hemodynamics undergoing brain computed tomography (CT) scans.
• Infants were allocated to receive either 0.1 mg/kg or 0.3 mg/kg of IV midazolam.
• Onset, duration, success rate, vital sign changes, and side effects were compared between groups.

Main Results:

• The 0.3 mg/kg midazolam group showed a significantly higher success rate (60%) compared to the 0.1 mg/kg group (38.2%) (p=0.018).
• Over half of the patients (50.9%) required additional sedation with ketamine or midazolam.
• No significant differences were observed in the onset of action or effects on vital signs between the two doses.

Conclusions:

• Intravenous midazolam at 0.3 mg/kg is more effective and provides a longer duration of action for procedural sedation in Iranian infants compared to 0.1 mg/kg.
• Both doses were comparable in terms of onset of action, impact on vital signs, and safety profile.
• The findings support the use of 0.3 mg/kg midazolam for improved sedation success in this pediatric population.